在医美行业增速整体放缓的背景下,全球最大的玻尿酸原料供应商华熙生物(688363.SH)正在积极寻求新的增长曲线。9月8日,华熙生物通过全资子公司华熙生物科技(香港)有限公司,以每股12港元的价格认购圣诺医药(02257.HK)约1735.24万股新股,总投资额达1.38亿港元,交易完成后持股比例达9.44%。这笔战略投资不仅为华熙生物带来了股价上的即时回报——截至9月11日收盘,圣诺医药股价已涨...
Source Link在医美行业增速整体放缓的背景下,全球最大的玻尿酸原料供应商华熙生物(688363.SH)正在积极寻求新的增长曲线。9月8日,华熙生物通过全资子公司华熙生物科技(香港)有限公司,以每股12港元的价格认购圣诺医药(02257.HK)约1735.24万股新股,总投资额达1.38亿港元,交易完成后持股比例达9.44%。这笔战略投资不仅为华熙生物带来了股价上的即时回报——截至9月11日收盘,圣诺医药股价已涨...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.